Poolbeg Pharma is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets.
Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.
Experienced Team with Proven Track Record
We are led by a highly experienced management team with expertise in trial execution, deal-making, company building, and generating shareholder returns.
Learn More
High Value Programmes
POLB 001: Potentially breakthrough oral preventative therapy for cancer immunotherapy-induced CRS with FDA Orphan Drug Designation. POLB 001 has the potential to transform the cancer immunotherapy field, with an estimated market opportunity of <US$10B. By making cancer immunotherapy treatment safer through the prevention of the life-threatening side effect, CRS, POLB 001 has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals. As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.
Oral encapsulated GLP-1 programme: A patient-friendly therapy targeting the growing obesity market using proprietary drug delivery technology. Oral GLP-1 options remain limited yet highly sought after, 65% of patients that discontinued treatment stated they would prefer oral alternatives1 An effective oral GLP-1 could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments.
Two successful AI-led discovery programmes: Transforming human challenge trial data into potential clinical candidates for RSV and influenza
Learn More
Investor Relations
Poolbeg is headquartered in London and is publicly traded on the London Stock Exchange
AIM: POLB
VISIT INVESTOR CENTRE